**Core tip:** Hepatocellular carcinoma (HCC) is characterized by early formation of portal vein tumor thrombus (PVTT). Even after surgical removal of the tumors with PVTT in HCC patients, early recurrence has been frequently reported due to intrahepatic metastasis from PVTT. There have been reports of long-term survival after hepatectomy in patients with macroscopic PVTT. The operative mortality of major hepatectomy for HCC patients with macroscopic PVTT has not been well documented or discussed. To this end, we reviewed recent literature on the significance of hepatectomy in HCC with macroscopic PVTT with respect to the long-term survival and mortality.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) is characterized by early formation of portal vein tumor thrombus (PVTT)\[[@B1]\]. An important prognostic factor and predictor for HCC recurrence is PVTT\[[@B2],[@B3]\]. The effectiveness of transarterial chemoembolization (TACE) for HCC with PVTT remains unclear\[[@B4],[@B5]\] though TACE is included in the treatment for HCC with tumor thrombus in the main portal branch\[[@B6]\]. However, it was suggested that hepatic arterial infusion chemotherapy might be a hopeful approach\[[@B7],[@B8]\]. Because the median survival for untreated patients with PVTT is only 2.7 mo, this suggestion is especially relevant\[[@B9]\]. Hepatectomy for advanced HCC with removal of PVTT might also warrant consideration as an adjuvant treatment though it is usually performed as an emergency operation to avoid lethal complications\[[@B10]\]. Early recurrence has been reported in many cases due to intrahepatic metastasis from PVTT\[[@B11]\] even after tumors with PVTT in HCC patients was surgically removed. On the other hand, there have been reports of long-term survival after hepatectomy in patients with macroscopic portal invasion\[[@B12],[@B13]\], but whether this treatment is optimal for patients with major PVTT remains controversial. Moreover, the operative mortality of major hepatectomy for HCC with macroscopic PVTT has not been well documented and reviewed. Therefore, we review literature published after January 2000 about the significance of hepatectomy in HCC with macroscopic PVTT with respect to long-term survival and mortality.

SURGICAL GUIDELINES FOR RESECTION IN HCC WITH PVTT
==================================================

Because the cancer has already disseminated at this stage, leading to high rates of recurrence, hepatectomy for HCC with portal invasion is not recommended in the barcelona clinic liver cancer (BCLC) staging and treatment strategy. Portal invasion is associated with the development of metastatic nests, with higher incidence in tumors exhibiting microvascular invasion and/or satellite lesions\[[@B14]\].

According to the BCLC staging classification, sorafenib is the treatment of choice for HCC with macroscopic portal invasion (BCLC stage C). The efficacy of sorafenib in the treatment of advanced HCC was recently confirmed by the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial. In that report, the median overall survival was 7.9 mo in the placebo group compared to 10.7 mo in the sorafenib group. The benefit of sorafenib was consistent in the pre-specified stratification groups that included patients with the worst prognosis, such as those with macroscopic vascular invasion\[[@B15]\]. According to the BCLC staging classification, hepatectomy is contraindicated in HCC with Vp3 (tumor thrombus in the first branch of the portal vein) or Vp4 (tumor thrombus extension to the trunk or to the opposite side branch of the portal vein) and should only be performed in patients with small single tumors without signs of portal hypertension or hyperbilirubinemia. On the other hand, the proposed treatment for HCC with minimal portal invasion, such as Vp1 (tumor thrombus distal to the second branches of the portal vein) and Vp2 (tumor thrombus in the second branches of the portal vein), is hepatectmy combined with TACE in the Japan Society of Hepatology (JSH) algorithm\[[@B16]\]. Indeed, when hepatectomy was performed in selected patients affected by HCC with macroscopic PVTT, in combination with either postoperative arterial infusion therapy or preoperative TACE, long-term survival was achieved\[[@B13],[@B17]\].

In the 17^th^ Nationwide Follow-up Survey of Primary Liver Cancer report in Japan, it was stated that the survival rates of 976 hepatectomized HCC patients with Vp3 or Vp4 were 50.4%, 25.8% and 18.4% at 1, 3 and 5 years, respectively\[[@B1]\].

HEPATECTOMY WITH MULTIDISCIPLINARY TREATMENT FOR PVTT
=====================================================

The prognosis of the HCC patients with PVTT in the first branch or main trunk is very poor, with a median survival of only 2.7 mo if appropriate treatments are not employed\[[@B9]\]. However, in the present literature search, we identified instances of long-term survival after hepatectomy. The range of overall survival (OS) rates for patients who received hepatectomy without multidisciplinary treatment were from 14.2% to 86.5% at 1 year, 0% to 60.4% at 3 years and 0 to 33.3% at 5 years (Table [1](#T1){ref-type="table"}). On the other hand, the range of the OS rates for patients who received hepatectomy with multidisciplinary treatment were from 0% to 100% at 1 year, 14.0% to 74.0% at 3 years and 21.5% to 42.0% at 5 years (Table [1](#T1){ref-type="table"}). From these data, we can see that the OS rates of patients who received hepatectomy with multidisciplinary treatment tended to be superior to those of patients who did not receive multidisciplinary treatment. This favorable outcome was achieved when hepatectomy was pre- or postoperatively combined with multidisciplinary treatment. The multidisciplinary treatments included the following: Preoperative radiotherapy (RT) on PVTT in the main trunk or first branch\[[@B12]\]; preoperative TACE\[[@B13]\]; subcutaneous administration of interferon-alpha (IFN-α) and intra-arterial infusion of 5-fluorouracil (5-FU)\[[@B17]\]; Epi-Adriamycin/cisplatin+5-FU\[[@B18]\]; cisplatin+5-FU infused in the portal vein or in the proper hepatic artery\[[@B19]\]; PIAF regimen (cisplatin, doxorubicin and 5-FU locally administered in the portal vein with subcutaneous injection of IFN-α)\[[@B20]\]; adjuvant chemotherapy (5-FU and Adriamycin) *via* the portal vein\[[@B21]\]; postoperative TACE\[[@B22]-[@B24]\]; percutaneous isolated hepatic perfusion (PIHP)\[[@B25]\]; and hepatic artery infusion and/or portal vein chemotherapy\[[@B26]\].

###### 

Surgical outcome of hepatectomy for hepatocellular carcinoma patients with portal vein thrombus

  **Ref**.                          **Vp type**                            **Patients**   **Child-Pugh A (%)**   **HBV (%)**   **OS, 1 yr (%)**   **OS, 3 yr (%)**   **OS, 5 yr (%)**   **Treatment**
  --------------------------------- -------------------------------------- -------------- ---------------------- ------------- ------------------ ------------------ ------------------ -----------------------------------------
  Ohkubo et al\[[@B11]\] 2000       Vp234                                  47             91.5                   42.6          53.9               33.2               23.9               
  Minagawa et al\[[@B13]\] 2001     Vp234                                  18             NS                     44.4          82                 42                 42                 Preop TACE
  Fan et al\[[@B26]\] 2003          Vp34                                   19             78.9                   NS            14.2               0                  0                  
                                    Vp34                                   64             78.1                   NS            37.6               14                 NS                 Postop PVI HAI
  Capussotti et al\[[@B42]\] 2004   Vp234                                  13             NS                     NS            NS                 18.5               18.5               
  Zhou et al\[[@B19]\] 2006         Vp234                                  381            NS                     90            47                 16                 12                 
  Ikai et al\[[@B27]\] 2006         Vp34                                   78             NS                     30.8          45.7               21.7               10.9               
  Chen et al\[[@B49]\] 2006         Vp234                                  438            NS                     NS            52.1               16                 11.8               
                                    Vp23                                   286            13.3                   60.1          58.7               22.7               18.1               
                                    Vp34                                   152            NS                     62.5          39.5               5.7                0                  
  Nagano et al\[[@B17]\] 2007       Vp3                                    15             NS                     66.7          100                74                 NS                 Postop 5-FU/IFN
                                    Vp3                                    15             NS                     40            41                 22                 NS                 
  Kamiyama et al\[[@B12]\] 2007     Vp34                                   15             100                    66.7          86.2               43.5               34.8               Preop radiation
                                    Vp34                                   28             85.7                   64.3          39                 13.1               13.1               
  Liang et al\[[@B20]\] 2008        Vp34                                   33             54.5                   93.9          46.8               14.4               NS                 Postop PIAF
                                    Vp34                                   53             69.8                   92.5          23.4               5.8                NS                 
  Peng et al\[[@B22]\] 2009         Vp34                                   51             86.3                   NS            50.9               33.8               21.5               Postop TACE
                                    Vp34                                   53             86.8                   NS            33.3               17                 8.5                
  Ban et al\[[@B57]\] 2009          Vp34                                   45             66.7                   42.2          69.6               37.4               22.4               
  Shi et al\[[@B48]\] 2010          Vp3                                    169            99.4                   81.1          38.2               17.7               NS                 
                                    Vp4                                    78             97.4                   87.2          24.7               3.6                NS                 
                                    Vp4[1](#T1FN1){ref-type="table-fn"}    20             95                     90            18.3               0                  NS                 
  Zhou et al\[[@B21]\] 2011         Vp34                                   21             NS                     NS            47                 22                 NS                 
                                    Vp34                                   38             NS                     NS            70                 20                 NS                 Adjuvant chemotherapy *via* portal vein
  Matono et al\[[@B45]\] 2012       Vp34                                   19             NS                     55.2          62.1               24.1               17.2               
                                    Vp34[2](#T1FN2){ref-type="table-fn"}   10             NS                     NS            38.5               0                  0                  
  Chen et al\[[@B50]\] 2012         Vp34                                   88             84.1                   89.8          31.1               18.3               15.2               
  Peng et al\[[@B46]\] 2012         Vp3                                    68             NS                     NS            46.3               17.2               17.2               
                                    Vp4                                    83             NS                     NS            32.5               3.6                3.6                
                                    Vp4[1](#T1FN1){ref-type="table-fn"}    23             NS                     NS            21.7               0                  0                  
  Tang et al\[[@B43]\] 2013         Vp234                                  186            91.9                   85.5          40.1               17                 13.6               
  Li et al\[[@B58]\] 2013           Vp3                                    10             100                    100           43                 16                 NS                 
                                    Vp3[3](#T1FN3){ref-type="table-fn"}    20             100                    90            32                 11                 NS                 
  Chok et al\[[@B47]\] 2014         Vp3                                    71             95.8                   90.1          45.8               22.7               11.2               
                                    Vp3[4](#T1FN4){ref-type="table-fn"}    10             90                     100           50                 12.5               12.5               
                                    Vp34[5](#T1FN5){ref-type="table-fn"}   7              85.7                   100           28.6               14.3               14.3               
  Fukumoto et al\[[@B25]\] 2014     Vp234                                  41             NS                     NS            80.5               32.4               NS                 Postop PIHP
  Yamamoto et al\[[@B44]\] 2015     Vp34                                   10             NS                     NS            NS                 NS                 30                 
  Pesi et al\[[@B59]\] 2015         Vp3                                    21             NS                     NS            60                 39                 10                 
  Kojima et al\[[@B18]\] 2015       Vp34                                   27             92.6                   33.3          77.8               48.2               25.9               Postop HAIC (FP, epi-ADM)
                                    Vp34                                   25             88                     32            68                 32                 12                 
  Xiao et al\[[@B60]\] 2015         Vp2                                    28             NS                     NS            53.6               25                 25                 
                                    Vp3                                    38             NS                     NS            39.5               15.8               5.3                
  Bai et al\[[@B23]\] 2016          Vp23                                   51             92.2                   22            19.6               NS                 NS                 
                                    Vp23                                   31             96.8                   19            53.3               NS                 NS                 Postop TACE
                                    Vp23                                   10             100                    30            71.1               NS                 NS                 Postop radiation
  Zheng et al\[[@B51]\] 2016        Vp234                                  96             78.1                   58.3          86.5               60.4               33.3               
  Li et al\[[@B30]\] 2016           Vp4                                    39             88.9                   82.2          69                 NS                 NS                 Preop radiation
                                    Vp23                                   50             84                     88            35.6               NS                 NS                 
  Ye et al\[[@B24]\] 2016           Vp4                                    54             NS                     85.2          0                  NS                 NS                 Postop TACE
  Hamaoka et al\[[@B33]\] 2017      Vp34                                   7              100                    NS            100                71                 NS                 Preop radiation, HAIC (FP, IFN/5-FU)

Tumor thrombi involving the superior mesenteric vein;

Non-curative resection;

Hepatectomy with caudate lobe;

PVTT extending to or beyond the portal vein bifurcation, treated by en bloc resection followed by portal vein reconstruction;

PVTT extending to or beyond the portal vein bifurcation, treated by thrombectomy. OS: Overall survival; HBV: Hepatitis B virus; Vp2: Tumor thrombus in the second branches of the portal vein; Vp3: Tumor thrombus in the first branch of the portal vein; Vp4: Tumor thrombus extension to the trunk or the opposite-side branch of the portal vein; TACE: Transarterial chemoembolization; PVI: Portal vein infusion; HAI: Hepatic arterial infusion; PIAF: Cisplatin, doxorubicin and 5-fluorouridine (5-FU) locally administered in the portal vein with subcutaneous injection of interferon-α; PIHP: Percutaneous isolated hepatic perfusion; FAIT: FU arterial infusion and interferon therapy; HAIC: Hepatic arterial infusion chemotherapy; FP: Cisplatin+5-FU; ADM: Adriamycin; NS: Not stated.

It was reported that the survival periods of approximately 10% of patients with tumor thrombi in the first branch and the portal trunk is more than 5 years following hepatectomy and that postoperative multidisciplinary treatments, including local and systemic adjuvant chemotherapy, are required in addition to hepatectomy to prevent intrahepatic metastasis\[[@B27]\]. Fukumoto et al\[[@B25]\] described that the efficacy of PIHP for hepatectomized patients with macroscopic PVTT had a median OS of 23 mo compared with a 6.5 mo median survival for patients treated with sorafenib\[[@B15]\]. However, PIHP treatment requires special equipment/expertise that is not currently available outside of Kobe University. On the other hand, Minagawa et al\[[@B13]\] reported the survival rate of 42% at 5 years for patients who underwent hepatectomy with preoperative TACE, which can be easily performed in any center, with only 9 cases exhibiting portal vein invasion in the second-order branches. It was reported that treating 15 cases of HCC with PVTT using FU arterial infusion and interferon therapy (FAIT) in addition to surgery, and 100% of the patients survived more than 1 year. In contrast, 10 patients (67%) died within 1 year without FAIT and surgery\[[@B17]\]. Peng et al\[[@B22]\] conducted a randomized controlled trial and showed that postoperative TACE enhances the effect of liver resection combined with PVTT removal. Estimated 1-, 3- and 5-years survival rates were better in the TACE group (50.9%, 33.8%, and 21.5%, respectively) than in the control group (33.3%, 17.0%, and 8.5%, respectively).

Liang et al\[[@B20]\] reported that the efficacy of intra-portal infusion chemotherapy using the PIAF regimen. They describe their procedure for administration of chemotherapeutic agents into portal vein as an attempt to kill the residual cancer cells in the portal venous system and subsequently curtail postoperative cancer recurrence. Moreover, another randomized controlled trial reported that postoperative TACE combined with portal vein chemotherapy is beneficial for patients with HCC complicated by PVTT but that the long-term efficacy of this approach is uncertain\[[@B28]\]. A combination of hepatectomy and preoperative RT has been reported to be effective for PVTT in the first branch or main trunk\[[@B12]\]. The survival rates at 1-, 3-, and 5-year were 100%, 53.3%, and 40.0%, respectively. Therefore, one of the abovementioned perioperative treatments combined with hepatectomy for HCC with PVTT might be necessary to prolong patient survival, though which of these options are superior cannot be concluded from this review. More appropriate regimens of perioperative treatment continue to be developed. Because Ando et al\[[@B7]\] reported that hepatic arterial infusion chemotherapy (HAIC) with 5-FU and low-dose cisplatin may be a beneficial therapeutic option for patients with HCC with PVTT in the main portal trunk or in the first portal branch or in the second portal branch; this regimen may be promising as adjuvant therapy for hepatectomy in HCC with macroscopic PVTT.

As a curative treatment for HCC with PVTT, only hepatectomy might be insufficient, and multidisciplinary treatments must be required because portal invasion is associated with the development of metastatic nests.

Significance of local treatment for PVTT
----------------------------------------

What about targeting PVTT for local treatment? Yamanaka et al\[[@B29]\] reported that the portal pedicles should be divided before liver parenchymal dissection during segmentectomy and lobectomy to decrease the chance of dissemination of the intravasated cancer cells because the cancer cells can dislodge into the portal venous stream during hepatectomy for HCC. From this point of view, targeting the PVTT to prevent cancer cell dissemination is a desirable approach. It was reported that preoperative radiation on the PVTT caused the tumor thrombus to become completely necrotic based on pathological examination, and 5 (83.3%) of the 6 patients survived for over 2 years after treatment\[[@B12]\]. Li et al\[[@B30]\] also demonstrated that better postoperative survival outcomes were provided by neoadjuvant radiotherapy before partial hepatectomy than partial hepatectomy alone for patients with HCC containing the main portal tumor thrombus. In 12 of 45 patients, the extent of PVTT after radiotherapy was significantly reduced, with the remaining 31 showing partial response (PR) and stable disease (SD) or two with progressive disease (PD)\[[@B30]\]. Because the tolerance of the liver for RT is low, RT for HCC has been limited to palliative treatment\[[@B31],[@B32]\]. However, for the treatment of HCC, the effects of a high dose of local RT have been investigated\[[@B12],[@B30]\]. Minagawa et al\[[@B13]\] described that radiation hepatitis did not occur in any of their patients and no apparent late radiation-induced complications were noted in any patients. For this reason, preoperative external RT was targeting the PVTT, not the whole tumor. By their method of RT, the irradiation in the normal liver tissue was minimized and the RT dose was increased without significantly increasing toxicity. Good survival outcome of hepatectomy with preoperative TACE for HCC patients with PVTT was reported\[[@B13]\]. Pathological examination detected necrosis of the PVTT in these patients. Therefore, the dissemination of HCC cells in the portal vein decrease because preoperative TACE or RT in PVTT induces necrosis. Consequently, these preoperative treatments might prevent HCC recurrence. Moreover, Hamaoka et al\[[@B33]\] reported that hepatectomy after down-staging with 3D-CRT for PVTT combined with HAIC for advanced HCC is safe and results in long-term survival outcomes. Hepatectomy for patients affected by HCC with PVTT might prolong survival in conjunction with local treatment targeting PVTT: RT or TACE.

Operative mortality of hepatectomy for PVTT
-------------------------------------------

Hepatectomy was indicated for living donor liver transplantation and the following liver tumors: Metastatic liver tumor, HCC, biliary malignancy. Of all the local treatments, hepatectomy for HCC had the highest local controllability and yielded a good survival outcome\[[@B34],[@B35]\]. The liver functional reserve was decreased in almost all the patients with HCC because almost of patients with HCC had hepatitis B and/or hepatitis C viral infection and therefore had chronic hepatitis or cirrhosis\[[@B1]\]. Patients with liver cirrhosis decreased reticuloendothelial system functions, had elevated portal venous pressures, and impaired liver regeneration and coagulopathy\[[@B36]\]. Therefore, the mortality rates of hepatectomy in patients with liver cirrhosis was high form 8.9% to 19.6%\[[@B37]\]. On the other hand, recent advances in pre- and postoperative care, the decision criteria for hepatectomy and indications for hepatectomy and surgical techniques have been applied to extended hepatectomy\[[@B38]-[@B40]\]. Although operative mortality is not avoided even in donor hepatectomy for living donor liver transplantation, major hepatectomy become more safe by these preoperative evaluations\[[@B41]\].

There were 6 papers that reported mortality within 30 d. In Ohkubo et al\[[@B11]\]'s series, one patient died within 1 mo of the operation due to liver failure. In Capussotti et al\[[@B42]\]'s report, two patients died within 30 d due to postoperative bleeding and liver failure. In Ikai et al\[[@B27]\]'s report, patients who died within 30 d were 3, two from growth of the extrahepatic metastases and another because of pulmonary bleeding. There were 2 deaths (2.3%) recorded within 30 d after the operation due to operative mortality in Liang et al\[[@B20]\]'s paper. Two patients died within 30 d of surgery due to hepatic decompensation in Tang et al\[[@B43]\]'s study. Yamamoto et al\[[@B44]\] described one patient dying within 30 d of the operation due to acute renal failure. Thirteen papers mentioned mortality or operative mortality without reporting times. No mortality was described in six of these papers. The other 7 papers showed the number of patients or percentage of mortality. Fan et al\[[@B26]\] reported an operative mortality of 4.8%. In the control group, two patients died from operative complications in Peng et al\[[@B22]\]'s study. One patient in Matono et al\[[@B45]\]'s report died of operative morbidity. In Peng et al\[[@B46]\]'s report, there was one in-hospital postoperative death due to liver failure. The overall hospital mortality was 3.4% (*n* = 3) in Chock et al\[[@B47]\]'s study. There was one in-hospital death after the operation caused by postoperative bleeding (*n =* 169) in Shi et al\[[@B48]\]'s series. Operative mortality of Group A was 0% and that of Group B was 2.6% in Chen et al\[[@B49]\]'s paper. Chen et al\[[@B50]\] reported a mortality of 4.5%. Ye et al\[[@B24]\] reported that 5 patients died (9.3%) (liver failure: 3, serious infection: 1, and heart failure: 1). Zheng et al\[[@B51]\] reported that 1 in-hospital postoperative death (1.0%) occurred in the hepatic resection group, caused by a serious postoperative infection. Mortality on postoperative day 38 and 58 was described in studies by Capussotti et al\[[@B42]\] and Minagawa et al\[[@B13]\], respectively (Table [2](#T2){ref-type="table"}).

###### 

Patient mortality

                        **Ref**.                     **Patient number or percent**   **Cause of death**
  --------------------- ---------------------------- ------------------------------- -------------------------------------------------
  Within 30 d                                                                        
                        Ikai et al\[[@B27]\]         3                               Pulmonary bleeding
                                                                                     Extrahepatic growth
                        Yamamoto et al\[[@B44]\]     1                               Renal failure
                        Ohkubo et al\[[@B11]\]       1                               Liver failure
                        Capussotti et al\[[@B42]\]   2                               Postoperative bleeding
                                                                                     Liver failure
                        Liang et al\[[@B20]\]        2                               
                        Tang et al\[[@B43]\]         2                               Decompensation
  38 d                                                                               
                        Capussotti et al\[[@B42]\]   1                               Sepsis
  58 d                                                                               
                        Minagawa et al\[[@B13]\]     1                               Liver failure
  Operative mortality                                                                
                        Fan et al\[[@B26]\]          4.80%                           
                        Peng et al\[[@B22]\]         2                               Operative complication
                        Matono et al\[[@B45]\]       1                               
                        Peng et al\[[@B46]\]         1                               Liver failure
                        Chock et al\[[@B47]\]        3.40%                           
                        Shi et al\[[@B48]\]          1                               Postoperative bleeding
                        Zheng et al\[[@B51]\]        1                               Serious postoperative infection
                        Ye et al\[[@B24]\]           9.30%                           Liver failure, serious infection, heart failure
  Mortality                                                                          
                        Chen et al\[[@B49]\]         0%                              
                                                     2.60%                           
                        Nagano et al\[[@B17]\]       0%                              
                        Kamiyama et al\[[@B12]\]     0%                              
                        Ban et al\[[@B57]\]          0%                              
                        Chen et al\[[@B50]\]         4.50%                           
                        Fukumoto et al\[[@B25]\]     0%                              
                        Li et al\[[@B30]\]           0%                              

When an HCC with major PVTT is surgically resected, a major hepatectomy should be performed with removal of the parenchyma fed by the portal vein obstructed by the PVTT vein. This operative procedure is quite technically complicated. In Asiyanbola et al\[[@B52]\]'s report, the type of operative procedure (more than or equal to hemi-hepatectomy vs less than hemi-hepatectomy) was related with in-hospital mortality and, specifically, patients who underwent more than or equal to a hemi-hepatectomy had a mortality rate of 6.5% compared with 4.1% for patients who underwent less than a hemi-hepatectomy. Therefore, major hepatectomy requires a very refined technique\[[@B52]\]. However, the operative mortality for hepatectomy in HCC with macroscopic PVTT has not been discussed. In the present review, the highest rate of operative mortality found in the literature was 9.3%\[[@B24]\]. The rest were not as high compared to the rates reported by Asiyanbola et al\[[@B52]\], though the mortality data were represented in a variety of ways. Major hepatectomy for HCC with macroscopic PVTT has been safely performed in many cases. The estimated cause was that the majority of patients described in this review paper had a Child-Pugh A and were infected with HBV (Table [1](#T1){ref-type="table"}) and thus had a good liver function reserve. Therefore, we propose that the indication for hepatectomy in HCC with major PVTT should be expanded.

LONG-TERM SURVIVAL-RELATED FACTORS: THE EXTENT OF THE TUMOR THROMBUS
====================================================================

What are the long-term survival-related factors? Shi et al\[[@B48]\] previously classified PVTT into 4 groups by the extent of the tumor thrombus. Patients of types I and II: PVTT located in the segmental, sectoral, or right and/or left portal veins showed significantly better survival than those of types III and IV: PVTT extended to the main trunk of the portal vein or the superior mesenteric vein. Therefore, they concluded that hepatectomy with thrombectomy is justified in selected patients with HCC and PVTT located in the first, second, or lower branch of the portal vein. Zheng et al\[[@B51]\] also reported that the long-term survival in patients with type I and II PVTT was remarkably improved compared with in patients with type III and IV PVTT. Moreover, Kokudo et al\[[@B53]\] reported data from the nationwide survey of patients with primary liver cancer performed by the Liver Cancer Study Group of Japan, which stated that the survival benefit of liver resection was statistically significant only in patients with PVTT invading the main trunk or contralateral branch. From these data, while HCC with PVTT located in the first or second branch of the portal vein might be a relatively good indication for hepatectomy, hepatectomy for HCC combined with PVTT in the contralateral branch or main trunk should be performed after careful consideration.

Long-term survival-related factors: Liver function
--------------------------------------------------

Ikai et al\[[@B27]\] reported that the absence of ascites, prothrombin activity, and tumor diameter are independent prognostic factors reflecting portal hypertension, liver function and tumor status, respectively. Kondo et al\[[@B54]\] reported negative prognostic factors of hepatectomized patients with PVTT, including age \< 60 years and factors related to liver function: Total serum bilirubin \> 0.8 mg/dL and serum alkaline phosphatase \> 300 IU/mL. Pawlik et al\[[@B55]\] concluded that patients with HCC and the major vascular invasion of the main portal or hepatic vein branches derive long-term resection benefits if they have no, or minimal, underlying fibrosis. In another report, the presence of fibrosis: Moderate to severe was the individual significant predictive factor on multivariate analysis that was related with worse short-term (≤ 6 mo) and long-term (\> 6 mo) survival. In this paper, the authors argued that this result is due to postresection hepatic decompensation and to a "field cancerization"\[[@B56]\] effect in the cirrhotic liver, which places these patients at a higher risk for metachronous or synchronous disease. Most of the patients described in the studies we reviewed had a Child-Pugh A and were infected HBV (Table [1](#T1){ref-type="table"}). This status might be a requirement for adaptation to hepatectomy to prevent postoperative hepatic decompensation. Moreover, increased liver function reserve might lead to a better prognosis for patients with HCC complicated by PVTT after hepatectomy due to the prevention of synchronous or metachronous tumors. Of the HCC patients with macroscopic PVTT, the indication of hepatectomy should be restricted within good liver function reserve.

A limitation of this review is that most of the articles selected were published from Eastern Asian countries, and the findings may not be applicable to other regions of the world. A more comprehensive review of the global literature would be very valuable in the future.

CONCLUSION
==========

Hepatectomy might prolong the survival of patients with HCC with PVTT when the liver function reserve is preserved, such as in Child-Pugh score A cases. Effective multidisciplinary treatments may improve the prognosis and prevent recurrence due to disseminated cancer cells in these patients. Moreover, hepatectomy may be a feasible adjunct treatment for HCC with PVTT due to the current mortality rates after hepatectomy being quite low.
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